Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT05838781
Other study ID # CV185-837
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date December 4, 2023
Est. completion date May 16, 2024

Study information

Verified date May 2024
Source Bristol-Myers Squibb
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Atrial fibrillation (AF) is the most common clinical arrhythmia and the prevalence increases with age. AF increases the risk of ischaemic stroke fivefold and accounts for almost one-third of all strokes. As AF is often asymptomatic there are many undetected cases. It is important to find patients with AF and additional risk factors for stroke in order to initiate oral anticoagulation treatment, which can reduce the risk of an ischaemic stroke by 60-70%. Screening is recommended in European guidelines, however the most suitable population and the most suitable device for AF detection remain to be defined. The main objective of this study is to test the hypothesis that AF screening with 14-days continuous ECG monitoring in high-risk individuals identified with a risk prediction model is more effective than routine care in identifying patients with undetected AF. Effectively detecting AF among patients with risk factors for ischaemic stroke has the potential to decrease mortality and morbidity, stroke burden and costs for the society as a whole.


Description:

Objective(s): To compare the yield of atrial fibrillation (AF) using 14-days continuous ECG in a population aged ≥ 65 years with an increased risk for AF incidence according to the risk prediction model compared with standard of care in Region Halland. Study Population: Residents in Region Halland age 65 and above. Data Collection Methods: Electronic Health Records from Region Halland and 14-days continuous ECG recording using an ECG patch. Study design: Step 1: To calibrate the BMS/Pfizer risk prediction model (RPM), we will extract two cohorts retrospectively: the AF cohort with an AF diagnosis (patients with a record of incident AF diagnosis between January 1, 2016, and December 31, 2019 as an observation period), and the control cohort without any AF diagnosis in their history. We will include patients ≥45 years of age at index date, which is the first date of an AF diagnosis recorded in the observation period and a random pseudo index date during the observation period for the control group, to follow the original study. Specifically, we are looking to calibrate the intercept (α) for the logistic regression where we already have the 13 odd ratios for the 13 risk factors from the original study. Then in the next step for the prospective study, applying the RPM on the RPM cohort, the at-risk group will be extracted for randomization step, using the recommended cut-off value. Step 2: The population in Region Halland aged 65 years and above and free from AF will be randomized into two halves, creating a general cohort and an RPM cohort. In the general cohort, 1480 individuals will be further randomized into two arms, general/control and general/intervention. In the RPM cohort, the risk of incident AF will be calculated according to the Pfizer/BMS RPM. Those with a predicted risk for incident AF above a pre-specified threshold will then be randomly extracted into two arms, RPM/control and RPM/intervention (figure 1). Those randomized to the two intervention arms (general/intervention and RPM/intervention, n=740 each) will be invited to an AF screening intervention of 14-days continuous ECG using a patch device. Those randomized to the control groups (general/control and RPM/control, n=740 each) will not receive any information or intervention. The primary endpoint will be the difference in yield of newly diagnosed AF between the RPM/intervention and the general/control arms, where the latter will represent standard of care. Participants with newly diagnosed AF in the intervention arms will be offered consultation aiming at AF work-up and initiation of oral anticoagulation treatment.


Recruitment information / eligibility

Status Completed
Enrollment 2112
Est. completion date May 16, 2024
Est. primary completion date May 16, 2024
Accepts healthy volunteers No
Gender All
Age group 65 Years and older
Eligibility Inclusion Criteria: - Alive residents in the Halland region aged 65 or older without a recorded diagnosis of AF Exclusion Criteria: - Known atrial fibrillation - Death - No longer resident in Region Halland - Pacemaker, implantable cardioverter defibrillator or insertable monitor - Dementia - Other indication for OAC treatment (such as VTE, mechanical heart valve replacement, VTE prophylaxis post surgery, mitral stenosis, left side intracardial thrombus)

Study Design


Related Conditions & MeSH terms


Intervention

Diagnostic Test:
Risk prediction model
A risk prediction model (RPM) based on logistic regression. The RPM uses 13 variables accessible in healthcare registers to identify individuals with high future risk for developing AF. ICD-10 codes will be used.
14-days continuous ECG monitoring
14-days continuous ECG monitoring with an ECG patch.

Locations

Country Name City State
Sweden Karolinska Institutet Danderyd University Hospital Stockholm Outside US
Sweden Halland Hospital Varberg Varberg Outside US

Sponsors (6)

Lead Sponsor Collaborator
Bristol-Myers Squibb Halmstad University, Karolinska Institutet, Pfizer, Philips Healthcare, Region Halland

Country where clinical trial is conducted

Sweden, 

Outcome

Type Measure Description Time frame Safety issue
Other Proportion of patients starting oral anticoagulation treatment Proportion of patients with AF and treatment with anticoagulation in control and interventions arms in the general and RPM cohorts, respectively, during a 6-, 12- and 18-months period? 18 months
Other Feasibility of self-application of ECG patch To study uptake and feasibility of self-application of ECG patch. 14 days
Other AF yield during the first 24 and 48 hours Proportion of patients diagnosed with AF within the first 24 and 48 hours of ECG patch recording. 48 hours
Other Cost-effective analysis Cost-effectiveness analysis of the risk prediction model together with the ECG patch compared to standard care. The possibility to increase survival as a consequence of avoiding AF-related events will then be compared to increased screening costs as well as cost of treatment. 14 days
Primary Incident AF Incident AF on ECG screening (intervention arms) defined as at least one episode of AF or atrial flutter with a duration of at least 30 seconds on ambulatory ECG recording.
Incident AF registered in the Electronic Health Record during follow-up (all four arms).
14 days
Secondary Yield newly diagnosed AF: RPM/ intervention arm versus RPM/ control arm To compare the yield of newly diagnosed AF using 14-days continuous ECG in a population aged = 65 years with an increased risk for AF incidence according to the RPM compared with a population with increased risk according to the RPM without intervention. 14 days
Secondary Yield newly diagnosed AF: general/ intervention arm versus RPM/ control arm To compare the yield of newly diagnosed AF using 14-days continuous ECG in a general population aged = 65 years compared with a population with increased risk according to the RPM without intervention. 14 days
Secondary Yield newly diagnosed AF: general/ intervention arm versus general/ control arm To compare the yield of newly diagnosed AF using 14-days continuous ECG in a general population aged = 65 years compared with a general population without intervention. 14 days
See also
  Status Clinical Trial Phase
Recruiting NCT05654272 - Development of CIRC Technologies
Completed NCT04571385 - A Study Evaluating the Efficacy and Safety of AP30663 for Cardioversion in Participants With Atrial Fibrillation (AF) Phase 2
Terminated NCT04115735 - His Bundle Recording From Subclavian Vein
Completed NCT05366803 - Women's Health Initiative Silent Atrial Fibrillation Recording Study N/A
Completed NCT02864758 - Benefit-Risk Of Arterial THrombotic prEvention With Rivaroxaban for Atrial Fibrillation in France
Recruiting NCT05442203 - Electrocardiogram-based Artificial Intelligence-assisted Detection of Heart Disease N/A
Completed NCT05599308 - Evaluation of Blood Pressure Monitor With AFib Screening Feature N/A
Completed NCT03790917 - Assessment of Adherence to New Oral anTicoagulants in Atrial Fibrillation patiEnts Within the Outpatient registrY
Enrolling by invitation NCT05890274 - Atrial Fibrillation (AF) and Electrocardiogram (EKG) Interpretation Project ECHO N/A
Recruiting NCT05316870 - Construction and Effect Evaluation of Anticoagulation Management Model in Atrial Fibrillation N/A
Recruiting NCT05266144 - Atrial Fibrillation Patients Treated With Catheter Ablation
Not yet recruiting NCT06023784 - The Impact of LBBAP vs RVP on the Incidence of New-onset Atrial Fibrillation in Patients With Atrioventricular Block N/A
Recruiting NCT05572814 - Transform: Teaching, Technology, and Teams N/A
Recruiting NCT04092985 - Smart Watch iECG for the Detection of Cardiac Arrhythmias
Completed NCT04087122 - Evaluate the Efficiency Impact of Conducting Active Temperature Management During Cardiac Cryoablation Procedures N/A
Completed NCT06283654 - Relieving the Emergency Department by Using a 1-lead ECG Device for Atrial Fibrillation Patients After Pulmonary Vein Isolation
Recruiting NCT05416086 - iCLAS™ Cryoablation System Post-Market Clinical Follow-up (PMCF) Study N/A
Completed NCT05067114 - Solutions for Atrial Fibrillation Edvocacy (SAFE)
Completed NCT04546763 - Study Watch AF Detection At Home
Completed NCT03761394 - Pulsewatch: Smartwatch Monitoring for Atrial Fibrillation After Stroke N/A